Opie L H
Medical Research Council Ischaemic Heart Disease Research Unit, University of Cape Town Medical School, South Africa.
Drugs. 1993;46 Suppl 2:142-8. doi: 10.2165/00003495-199300462-00023.
Theoretically, it should be possible to match the requirements of individual patients with the pharmacological and clinical properties of the large number of antihypertensive drugs now available. The concept of automatic sequential stepped-care therapy is now largely outdated, but therapy of clinically important hypertension must be initiated with one agent. Diuretics remain a first-line option in the elderly and in Black patients, as do calcium antagonists. Outcome trials are available only for the elderly, and in these the benefits of initial diuretic therapy are well documented. Nonetheless, diuretics may often need to be co-prescribed with a beta-blocker or an adrenergic modifier such as methyldopa. beta-Blockers are preferred in patients with ischaemic heart disease or enhanced adrenergic drive, while alpha-blockers are preferred in patients with blood lipid abnormalities or prostatic problems. Calcium antagonists or angiotensin converting enzyme (ACE) inhibitors are being increasingly used as initial therapy when quality of life is important and metabolic neutrality is required. Calcium antagonists are more likely to be effective first-line therapy than ACE inhibitors in patients with a high salt intake, in patients with Raynaud's disease, when angina pectoris is present, and in Black patients. ACE inhibitors are preferred for combination with diuretic agents, and in the presence of congestive heart failure or low salt intake. Experimentally, both calcium antagonists and ACE inhibitors can prevent ischaemic ventricular fibrillation and atheroma. Combination therapy between these 2 drug classes is gaining increasing acceptance because of these theoretical advantages.(ABSTRACT TRUNCATED AT 250 WORDS)
从理论上讲,应该能够使个体患者的需求与目前大量可用降压药的药理和临床特性相匹配。自动序贯阶梯式治疗的概念现在在很大程度上已经过时,但临床上重度高血压的治疗必须从一种药物开始。利尿剂在老年人和黑人患者中仍然是一线选择,钙拮抗剂也是如此。仅针对老年人有疗效试验,在这些试验中,初始利尿剂治疗的益处有充分记录。尽管如此,利尿剂通常可能需要与β受体阻滞剂或肾上腺素能调节剂(如甲基多巴)联合使用。β受体阻滞剂在患有缺血性心脏病或肾上腺素能驱动增强的患者中更受青睐,而α受体阻滞剂在患有血脂异常或前列腺问题的患者中更受青睐。当生活质量很重要且需要代谢中性时,钙拮抗剂或血管紧张素转换酶(ACE)抑制剂越来越多地被用作初始治疗。在高盐摄入患者、患有雷诺病的患者、存在心绞痛的患者以及黑人患者中,钙拮抗剂比ACE抑制剂更有可能成为有效的一线治疗药物。ACE抑制剂更适合与利尿剂联合使用,以及在存在充血性心力衰竭或低盐摄入的情况下使用。在实验中,钙拮抗剂和ACE抑制剂都可以预防缺血性心室颤动和动脉粥样硬化。由于这些理论优势,这两类药物之间的联合治疗越来越被接受。(摘要截断于250字)